<DOC>
	<DOCNO>NCT00361595</DOCNO>
	<brief_summary>The purpose study evaluate adequacy zoledronic acid maintain bone mass two year treatment Forteo , postmenopausal woman .</brief_summary>
	<brief_title>Intervenous ( IV ) Zoledronic Acid After Forteo Postmenopausal Women</brief_title>
	<detailed_description>This single center open label proof concept study , recruit subject previously treat Forteo least 12 month . A screening period 3 6 week precede treatment period . At baseline visit , patient whose eligibility confirm treated ZA follow 12 month . Safety efficacy assess regular interval ( day one , day 10 , month 2 , month 6 , month 9 month 12 ) . Renal safety assess prior i.v . dose study medication , day 10 i.v . dose study medication 12 month . Bone density lumbar spine ( L1-4 ) total hip perform 6 month end 12 month treatment period . Biomarker analyse secondary endpoint perform day 10 , month 2 , month 6 , month 9 month 12 .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal woman age 85 , inclusive Finish treatment 12 month longer Forteo Signed informed consent prior initiation studymandated procedure . Hip spine DXA Tscore &gt; 1.0 Patients 25 ( OH ) vitamin D level less 15 ng/mL Visit 1 . ( Patient replete vitamin D 50,000 unit biweekly 2 month rescreened anytime 2 month continue Forteo . ) Baseline renal insufficiency ( calculated creatinine clearance le 40.0 mL/min ( MDRD ) Visit 1 and/or Visit 2 urine dipstick great equal 2+ protein without evidence contamination bacteriuria ( may repeat one time least week apart suspicion contamination ) . Patients calculate creatinine clearance equal great 40.0 mL/min less 60.0 mL/min serum creatinine great upper limit normal Visit 1 must retested Visit 1 2 . Patients calculate creatinine clearance great 60.0 mL/min serum creatinine within normal limit Visit 1 require retest . Patients require retest creatinine clearance Visit 1 2 excluded increase serum creatinine great 0.5 mg/dL Visit 1 Visit 2 . Serum calcium &lt; 8.5 &gt; 11.0 mg/dl Visit 1 AST ALT great twice upper limit normal Serum alkaline phosphatase great 1.5 time upper limit normal ( liver fraction ) No history retinopathy nephropathy especially presence uncontrollable IDDM Hb1 AC &gt; 10 % Hypersensitivity bisphosphonates Treatment biphosphonates Forteo Prior treatment i.v . biphosphonates Estrogen , calcitonin , raloxifene use prior Forteo treatment exclusion , concomitant therapy bone agent trial permit Any prior use strontium ranelate sodium fluoride Chronic use systemic corticosteroid ( oral i.v . ) within last year : NOTE : Use corticosteroid form topical cream , nasal inhaled formulation inject locally ( intraarticularly ) NOT exclusionary . Prior exposure anabolic steroid growth hormone within 6 month prior randomization Treatment investigational drug ( ) and/or device within 30 day prior randomization . History iritis uveitis , except secondary trauma , must resolve 2 year prior randomization . Cancer exclusion : Patients new diagnosis active treatment malignancy less equal 12 month prior Visit 1 . Patients evidence metastasis prior randomization , history metastasis Subjects evidence paraneoplastic syndrome , especially characterize hypercalcemia screen history Patients follow may include : basal cell squamous cell carcinoma skin , colonic polyp noninvasive malignancy remove , Carcinoma insitu ( CIS ) prostate ( Stage I ) surgically remove . Previous major solid organ bone marrow transplant recipient transplant wait list Any disease spine would preclude proper acquisition lumbar spine DXA ( L1L4 ) e.g. , implantable device , scoliosis , ankylose spondylitis , DJD . ( Less two lumbar spine vertebral body evaluable ) Active primary hyperparathyroidism hypoparathyroidism Subject complete thyroidectomy Active hyperthyroidism Hypothyroidism treat adequate replacement therapy History multiple myeloma Paget 's disease Patients severe dental problem current dental infection , recent impend dental surgery within three month dose Any medical psychiatric condition , opinion investigator , would preclude participant adhere protocol complete trial per protocol</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>forteo</keyword>
</DOC>